Board summary
Key figures
33,569
Registered population
54.8% aged 18–64
28.4%
Aged 65+
ICB 19.0% · England 17.9%
0.6%
Ethnic minority (non-White)
0.1% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 31.9% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
5,971
Hypertension register
+6.45% in 3 yrs · England +5.60%
284
SMI register
7.2% of Cheshire East (LAD)'s
498
COPD register
Reviews +4.39% in 3 yrs
Forecast to 2030
6,968
Hypertension patients, 2030
+997 on today
65.8%
QRISK ≥20% on statins, 2030
+3.43pp over 3 yrs
7.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma reviews fell while England rose.
Annual asthma reviews sit at 64.5% (England 65.7%) after falling 9.2% over three years (England +4.4%), leaving about 810 patients unreviewed.
Blood pressure and lipid control trail England.
Hypertension control is 64.2% (England 70.3%), QRISK ≥ 20% lipid therapy 58.3% (England 63.6%), and SMI BP checks 73.0% (England 83.4%).
Non-frail diabetes control and immunisations lead.
Non-frail diabetes HbA1c control reaches 66.4% (England 57.4%, +10.8% over three years), alongside 96.1% two-dose MMR coverage at age 5 (England 82.8%).
Population, age and ethnicity
Older patients represent 28.4% of the list, above national and borough benchmarks
Middlewood PCN operates as a single practice (Middlewood Partnership) serving 33,569 registered patients. The PCN has an older demographic profile: 28.4% (9,523 patients) are aged 65+, compared to 22.6% in Cheshire East (LAD), 19.0% in NHS Cheshire and Merseyside Integrated Care Board, and 17.9% in England. Adults aged 18–64 represent 54.8% and children aged 0–17 represent 16.8%. Census area data shows 99.4% White and 0.6% ethnic minority residents (Asian / Asian British 0.1%, Black / African / Caribbean / Black British 0.2%), though Census residence differs from registered list ethnicity.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 66.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.8 with 0.0% of patients residing in Core20 areas
Middlewood PCN records an average IMD decile of 8.8 (Middlewood Partnership records 9.1), against 7.1 in Cheshire East (LAD), 5.2 in NHS Cheshire and Merseyside Integrated Care Board, and 5.5 in England. Across Middlewood Partnership, 0.0% of registered patients live in Core20 areas (0 patients), versus 9.2% in Cheshire East (LAD), 31.9% in the ICB, and 21.0% in England, with 0 of 34 associated LSOAs in deciles 1 or 2. Inequality work may therefore prioritise clinical risk and inclusion groups rather than area deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
284
SMI register
0.83% recorded prevalence
87
Learning disability register
0.26% recorded prevalence
19
Care homes, 675 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
Recorded prevalence trails England for learning disability at 0.3% (87 patients; England 0.6%) and severe mental illness at 0.8% (284 patients; England 1.0%), alongside 19 catchment care homes (675 beds). Cheshire East records 8.8% providing unpaid care and 10 rough sleepers, which cannot be extrapolated locally. Lower recorded prevalence than England benchmarks may reflect case-finding differences, which a register audit against care home records would test.
Severe mental illness: physical health checks
Physical health checks for SMI patients show blood pressure checks at 73.0% (England 83.4%), BMI recorded at 66.3% (England 82.1%), and alcohol consumption records at 65.1% (England 81.8%). Shortfalls across checks leave metabolic and cardiovascular risks unaddressed in this cohort.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,971
Hypertension register
+6.45%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
+2.32pp
BP control, under 80
≤140/90 · +1.45pp aged 80+
+997
More patients by 2030
Forecast 6,968 (19.88%)
Hypertension case-finding and control
Middlewood PCN records 5,971 hypertension patients (17.5% prevalence, versus 17.3% in Cheshire East (LAD), 16.8% in NHS Cheshire and Merseyside Integrated Care Board, and 15.2% in England). Recent blood pressure checks reach 87.1% (England 90.0%), but patients treated to target sit at 64.2%, trailing Cheshire East (LAD) (69.8%), the ICB (69.1%), and England (70.3%). Control in patients under 80 is 58.8% (England 67.8%), and 74.8% in those aged 80 and over (England 81.2%). An unverified product projection indicates the register could grow by 997 to 6,968 patients by 2030. Blood pressure control trails national benchmarks across age groups, suggesting systematic treatment escalation and home monitoring reviews could improve control.
Lipids and statins
Patients with QRISK ≥ 20% on lipid lowering therapy reach 58.3%, trailing Cheshire East (LAD) (61.2%), NHS Cheshire and Merseyside Integrated Care Board (63.2%), and England (63.6%). Coverage among CKD patients is 63.3% (England 70.3%). Fewer at-risk patients receive lipid-lowering therapy than national rates imply, indicating that secondary prevention and high-risk recall audits should be.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 61,437 | £1.90 | £1.71 | £1.86 | £116,730 |
| Cardiovascular (all), 2025 | 87,490 | £3.69 | £4.37 | £3.33 | £322,838 |
For lipid-modifying drugs in 2026, the PCN prescribed 61,437 items at £1.90 each, above Cheshire East (£1.72), the ICB (£1.71), and England (£1.86). This represents £11,673 more than at the ICB's unit cost. Higher unit costs than system comparators indicate an opportunity for clinical pharmacists to review lipid-modifying formulary alignment.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−9.17%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.27%
Asthma prevalence, PCN 3-yr % change
Asthma reviews fell 9.2% over three years (England +4.4%) to 64.5% (England 65.7%), leaving about 810 of 2,273 register patients unreviewed. COPD prevalence is 1.5% (498 patients) with reviews at 67.9% (England 76.4%). Smoking cessation offers fell 6.3 pp (England +0.1 pp) to 85.8% (England 94.2%), and youth asthma second-hand smoking recording is 64.0% (England 78.8%). Falling review rates indicate structured recall and preventive advice across respiratory conditions require clinical prioritisation.
Cancer register and children's immunisation
Cancer prevalence is 5.8% (1,956 patients; England 3.8%). In children, age-5 MMR dose 2 reaches 96.1% (England 82.8%), trailing dose 1 (97.4%) by 1.3 pp but exceeding the 95.0% target. In contrast, 12-month 6-in-1 coverage is 89.8% (England 91.0%), sitting 5.2 pp below the 95.0% coverage target before reaching 94.5% at 24 months. Strengthening first-year recall is required to avoid delays in completing infant primary courses.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with a known stage in NHS Cheshire and Merseyside ICB (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. Known-stage cases comprised 72.8% of registered cancers. Reaching 75.0% requires about 2,640 extra early-stage diagnoses annually across the ICB. PCN cancer prevalence is 5.8% (1,956 patients). For the PCN, rigorous safety-netting and sustaining screening uptake are crucial to support timely presentation.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, East Cheshire NHS Trust achieved 53.4% on the cancer 62-day referral to treatment standard, 31.6 pp below the 85.0% standard, trailing Stockport NHS Foundation Trust (74.7%), Manchester University NHS Foundation Trust (72.8%), the ICB (76.2%), and England (71.2%). The trust met the 28-day faster diagnosis standard at 81.1% (standard 75.0%) and the 31-day standard at 96.3% (standard 96.0%). Six-week diagnostic waits stood at 16.2% overall, though MRI waits reached 26.6% (Stockport 1.4%). Prolonged treatment backlogs at the main acute provider may delay definitive care.
| Pathways within standard (%) | East Cheshire | Stockport | Manchester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.08 | 83.21 | 80.06 | 77.25 | 79.32 |
| 31-day treatment (96%) | 96.30 | 97.39 | 92.54 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 53.41 | 74.67 | 72.85 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Cheshire | Stockport | Manchester | England |
|---|---|---|---|---|
| MRI | 26.62 | 1.41 | 11.68 | 21.40 |
| CT | 11.49 | 2.93 | 14.66 | 9.92 |
| Echocardiography | 26.24 | 17.46 | 4.91 | 28.48 |
| Colonoscopy | 10.85 | 5.53 | 4.51 | 30.83 |
| Gastroscopy | 10.25 | 5.31 | 29.35 | 29.02 |
| All 15 DM01 tests | 16.17 | 14.08 | 8.98 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). In Jun 2026, Cheshire East residents accounted for 72,825 community care contacts across 21,910 patients, within 541,280 contacts across NHS Cheshire and Merseyside Integrated Care Board. Adults aged 65+ represented 60.8% of borough contacts (44,295 contacts). Borough referrals totalled 18,280 across 12,885 patients. High community service use is consistent with the PCN's older demographic profile.
Practice variation and patient experience
Middlewood Partnership achieved 80.0% good patient experience while clinical QOF achievement trailed England
In 2025/26, Middlewood Partnership attained 89.6% overall QOF points (England 92.5%). Clinical-domain achievement reached 88.4%, trailing England's 97.1%, whereas vaccination and immunisation reached 91.9% (England 55.2%). Personalised care adjustments across all domains were 7.0% (England 10.0%). Clinical achievement shortfalls alongside lower adjustment rates highlight an opportunity to review chronic disease pathways.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Middlewood | 172 | 0.0 | 58.4% | 76.4% | 80.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven of 25 tracked measures trail national progress alongside contracting clinical registers
Across 25 tracked measures, 11 trail England's three-year change. The widest lags are in asthma reviews, which fell 9.2% (England +4.4%), dementia prevalence, which fell 4.0% (England +6.0%), and learning disability prevalence, which fell 2.9% (England +5.4%). Smoking cessation offers also fell 6.3 pp (England +0.1 pp). Key three-year strengths include non-frail diabetes HbA1c control, which rose +10.8% (England +4.4%), and heart failure reviews, up +13.0% (England +8.7%). Register contraction may reflect coding or case-finding pauses, which validation audits against practice lists would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Dementia register
Learning disability register
Smoking support (SMI)
COPD register
Diabetes HbA1c control
Heart failure reviews
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 19 (675 beds) | n/a | Schools (catchment) | 40 | n/a |
| Children's centres | 1 | 14 | Places of worship | 29 | 272 |
| Libraries | 3 | 16 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 12 | 41 | Primary academies | 9 | 78 |
| Special schools | n/a | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma review completion is 64.5% (England 65.7%) and fell 9.2% over three years (England +4.4%), leaving about 810 of 2,273 register patients unreviewed. For discussion: Middlewood Partnership could run a single-template recall search and offer flexible review slots alongside inhaler prescribing checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension and lipid therapy escalation
Across 5,971 hypertension patients, treatment to target is 64.2% (England 70.3%; under-80s 58.8% vs 67.8%), and QRISK ≥ 20% lipid therapy is 58.3% (England 63.6%). For discussion: the PCN could establish pharmacist-led hypertension titration and high-risk QRISK lipid initiation clinics using structured searches. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Learning disability register validation
Recorded learning disability prevalence is 0.3% (87 of 33,569 patients) after falling 2.9% (England +5.4%), a modelled gap of +67 to +110 against borough (0.5%) and England (0.6%). For discussion: Middlewood Partnership could audit diagnostic codes and cross-check the register against social-care and care-home records where permitted. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult anticipatory care review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| SMI physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension treatment escalation audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Infant immunisation recall review (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Early diagnosis safety netting audit (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Telephone queue retention audit (p9) | GPPS callers held in a queue who waited until someone answered | — | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension and lipid therapy escalation (p12) | Hypertension register · Hypertension patients treated to target · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
